Posted by SLS on January 17, 2013, at 4:17:41
In reply to Re: just filled Minocycline-SLS, posted by poser938 on January 16, 2013, at 18:41:11
> > Poser seriously considering taking the 75mg dose tonight. It was after 3 doses that I got a headache. I'm wondering if it might help with the still positive titer for lymes? Best of luck and sure hope it helps you. Phillipa
>
> Earlier I took my 2nd dose of 100mgs. Still no effect or side effect. I'm probasbly going to give it 2 months tho.
> Jusdt going to maake sure I check my teeth for discolaration regularly.I would go at least 4 months with minocycline, as long as you are tolerating it well. 200 mg/day seems to be the dosage that is most often chosen in clinical trials (100 - 400 mg/day). To reiterate, the folks at Harvard / Mass General have seen people need as long as a year to reach full remission. This might be what one would expect if long-term reduction in inflammation is an important mechanism. In my experience, I felt a perceptible improvement in the first week. Over the last 4 months, I have been improving gradually. The improvement is not smooth, though. It is more like a saw-tooth pattern: up 2, back 1, up 2, back 1, up 2, etc. I had reached a level of perhaps 40% improved two days ago. Yesterday was a "recession". I felt pretty crappy, but not nearly as severely ill as my baseline depression. First thing this morning, I am recovering.
I wonder if there is an interplay between inflammation and hyperglutamatergic activity such that minocycline must reduce these two functional states simultaneously; all the while protecting against neurotoxicity and encouraging neurogenesis.
------------------------------------------------------
Minocycline:1. Is neuroprotective.
2. Reduces brain inflammation
3. Reduces the number of glutamate receptors.
4. Demonstrates antidepressant properties in mouse models of depression.
5. Is reported to act synergistically with noradrenergic antidepressants to treat depression - desipramine (but not fluoxetine).
6. Is reported to act synergistically with NMDA antagonists.
7. Reduces glutamate excitotoxicity by reducing the formation of quinolic acid, a NMDA agonist.
8. Reduces mitochondrial release of cytochrome C.
9. Modulates several signaling pathways.
10. Reduces microglial activation.
11. Has been reported anecdotally to successively treat depression.
12. Reduces the expression of lipopolysaccharide-induced pro-inflammation cytokines, an effect that acts as an antidepressant in animal models.
13. Increases neurite growth in response to nerve growth factor (NGF).
14. Inhibits high levels of PKC and GSK-3 alpha;
15. Decreases nitric oxide synthetase, thereby reducing free radicals which damage neurons and glia.
16. Reduces glutamate release.------------------------------------------------------
- ScottSome see things as they are and ask why.
I dream of things that never were and ask why not.- George Bernard Shaw
poster:SLS
thread:1035263
URL: http://www.dr-bob.org/babble/20130112/msgs/1035664.html